[News] Idelalisib: targeting PI3Kδ in B-cell malignancies

12:20 EST 31 Jan 2014 | The Lancet

Idelalisib—a first-in-class selective inhibitor of phosphoinositide-3-kinase delta, which is expressed only in haemopoietic cells—has been shown to be effective for treatment of B-cell malignancies in two clinical trials.

Original Article: [News] Idelalisib: targeting PI3Kδ in B-cell malignancies

NEXT ARTICLE

More From BioPortfolio on "[News] Idelalisib: targeting PI3Kδ in B-cell malignancies"

Search BioPortfolio:
Loading
Advertisement
Advertisement

Searches Linking to this Story